Endogenous Candida endophthalmitis: Who is really at risk? - 17/02/21
, Molly Fleece c, Allison Bloom d, Emily Lydon d, Wesley Yang e, Christopher Arnold c, David J. Weber f, g, Nwora Lance Okeke a, ⁎ Highlights |
• | The largest cohort of patients examining risk factors for Candida endophthalmitis. |
• | Novel finding of race as a risk factor. |
• | No association between major surgery, duration of candidemia, broad-spectrum antibiotics and diabetes diagnosis and diagnosis of Candida endophthalmitis as previously described in the literature. |
Abstract |
Objectives |
The Infectious Disease Society of America recommends that all patients with candidemia undergo a dilated retinal exam to exclude endogenous Candida endophthalmitis. Our objective was to determine if there are significant risk factors in candidemic patients for developing endogenous Candida endophthalmitis
Methods |
We conducted a retrospective study of all candidemic patients at three academic medical centers between 2012 and 2017. We extracted risk factors for Candida endophthalmitis based on prior literature and compared them between patients with and without endophthalmitis. We then built a multivariate logistic regression model to assess which ones were significant.
Results |
We found 771 patients with candidemia. 120 (15.6%) of these patients were diagnosed with Candida endophthalmitis. In our logistic regression analysis, central venous catheter presence (OR 8.35), intravenous drug use (OR 4.76), immunosuppression (OR 2.40), total parenteral nutrition recipient (OR 2.28), race (OR 1.65), age (OR 1.02), and gender (OR 0.57) were risk factors for developing Candida endophthalmitis. Additionally, Candida albicans was more likely to result in Candida endophthalmitis (OR 1.86).
Conclusions |
This cohort represents the largest study of risk factors for candidemic patients who developed endogenous Candida endophthalmitis. Based on our findings, clinicians should develop targeted and cost-effective strategies for endophthalmitis screening.
Le texte complet de cet article est disponible en PDF.Keywords : Candidemia, Candida endophthalmitis, Candida chorioretinitis
Plan
Vol 82 - N° 2
P. 276-281 - février 2021 Retour au numéro
Article précédent
- Safety of temporary interruption of antiplatelet therapy in dengue fever with thrombocytopenia
- Po Ying Chia, Htet Lin Htun, Yee Sin Leo, David Chien Lye
- Concerning the OptiGene Direct LAMP assay, and it’s use in at-risk groups and hospital staff
- Eleri S.W. Wilson-Davies, Adhyana I.K. Mahanama, Buddhini Samaraweera, Nusreen Ahmed, Simon Friar, Emanuela Pelosi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?